| Name | Title | Contact Details |
|---|
U V Iii Systems is a Bellingham, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Imperial Clinical Research Services is a Grand Rapids, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Minnetronix is committed to delivering high quality products and services. We believe that a quality system should be a tool for superior systems design and manufacturing, not a barrier. Our quality system reflects this philosophy. Minnetronix has
For more than 35 years, Kiddie Academy® has been a leader in education-based child care. The company serves families and their children ages 6 weeks to 12 years old, offering full time care, before- and after-school care and summer camp programs. Kiddie Academy`s proprietary Life Essentials® curriculum, supporting programs, methods, activities and techniques help prepare children for life. Kiddie Academy is committed to quality education and the highest standards in child care. About Kiddie Academy® Franchising Kiddie Academy International, Inc. is based in Maryland and over 190 academies located in 26 states. Approximately 70 additional academies are in development, with all future growth coming via franchising.
Kite Pharma, founded in 2009, is dedicated to the development and commercialization of novel cancer immunotherapy products designed to harness the power of a patient’s own immune system to fight tumor cells. Kite’s lead programs are in collaboration with the National Cancer Institute (NCI) and are being studied through the NCI’s Surgery Branch led by Steven A. Rosenberg, MD, PhD, who has pioneered immunotherapy approaches for cancer for more than two decades. This research has resulted in breakthrough clinical findings, including results from an NCI Phase 1/2a trial being presented at this year’s American Society of Hematology (ASH) Annual Meeting. Based on this progress and momentum, Kite plans to initiate a company-sponsored multicenter clinical program in aggressive non-Hodgkin’s lymphoma, with additional filings expected for other eACT™ products in diverse oncology indications.